Bristol-myers Squibb Compnay

Tamar Rosenbaum

Jay Patrick Powers

Petinka I Vlahova

Hunter Paul Shunatona

Maureen Kay Reilly

Mikhail Zibinsky

Maksim Osipov

Jennifer Leigh Nelson

Hilary Plake Beck

James Ross Walker

Ian Scott Young

San Kiang

Deniz Erdemir

Shih-Ying Chang

Donald Kientzler

The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-(1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

Amorphous and crystalline forms of IDO inhibitors

The present disclosure relates to amorphous and crystalline forms of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl) cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

A process for the production of a formulation of HIV attachment inhibitor piperazine tris salt prodrug compound involves dissolving the prodrug compound in a solvent to form a solution; adding a first quantity of a first anti-solvent to the solution; then dispersing a first quantity of HPMC in the solution; adding a second quantity of the first anti-solvent to the solution; dispersing a second quantity of HPMC in the solution; then adding a second anti-solvent to the solution so as to crystallize the compound with the HPMC and thereby form the formulation, wherein the second anti-solvent is a combination of acetone and isopropyl acetate (IPAC). The formulation is then washed, and dried.

Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Growing community of inventors

Princeton, NJ, United States of America

Tamar Rosenbaum